PTGS2 and neoplasm: Since we did not find a significant relationship between tumor driver mutations and COX-2 in clinical PPGL samples, molecular imaging could be applied in a personalized approach to pre-estimate whether a tumor is susceptible to COX-2-targeted treatment.